GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2A) » Definitions » 3-Year EPS without NRI Growth Rate

BioLine Rx (STU:YP2A) 3-Year EPS without NRI Growth Rate : 25.10% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioLine Rx 3-Year EPS without NRI Growth Rate?

BioLine Rx's EPS without NRI for the three months ended in Dec. 2023 was €-0.14.

During the past 3 years, the average EPS without NRI Growth Rate was 25.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 34.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of BioLine Rx was 45.30% per year. The lowest was 9.00% per year. And the median was 26.25% per year.


Competitive Comparison of BioLine Rx's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, BioLine Rx's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where BioLine Rx's 3-Year EPS without NRI Growth Rate falls into.



BioLine Rx 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


BioLine Rx  (STU:YP2A) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


BioLine Rx 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of BioLine Rx's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (STU:YP2A) Business Description

Industry
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (STU:YP2A) Headlines

No Headlines